Cargando…
Development of conjugated secondary antibodies for wildlife disease surveillance
Disease monitoring in free-ranging wildlife is a challenge and often relies on passive surveillance. Alternatively, proactive surveillance that relies on the detection of specific antibodies could give more reliable and timely insight into disease presence and prevalence in a population, especially...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368751/ https://www.ncbi.nlm.nih.gov/pubmed/37503338 http://dx.doi.org/10.3389/fimmu.2023.1221071 |
_version_ | 1785077573082939392 |
---|---|
author | Ochai, Sunday O. Crafford, Jan E. Kamath, Pauline L. Turner, Wendy C. van Heerden, Henriette |
author_facet | Ochai, Sunday O. Crafford, Jan E. Kamath, Pauline L. Turner, Wendy C. van Heerden, Henriette |
author_sort | Ochai, Sunday O. |
collection | PubMed |
description | Disease monitoring in free-ranging wildlife is a challenge and often relies on passive surveillance. Alternatively, proactive surveillance that relies on the detection of specific antibodies could give more reliable and timely insight into disease presence and prevalence in a population, especially if the evidence of disease occurs below detection thresholds for passive surveillance. Primary binding assays, like the indirect ELISA for antibody detection in wildlife, are hampered by a lack of species-specific conjugates. In this study, we developed anti-kudu (Tragelaphus strepsiceros) and anti-impala (Aepyceros melampus) immunoglobulin-specific conjugates in chickens and compared them to the binding of commercially available protein-G and protein-AG conjugates, using an ELISA-based avidity index. The conjugates were evaluated for cross-reaction with sera from other wild herbivores to assess future use in ELISAs. The developed conjugates had a high avidity of >70% against kudu and impala sera. The commercial conjugates (protein-G and protein-AG) had significantly low relative avidity (<20%) against these species. Eighteen other wildlife species demonstrated cross-reactivity with a mean relative avidity of >50% with the impala and kudu conjugates and <40% with the commercial conjugates. These results demonstrate that species-specific conjugates are important tools for the development and validation of immunoassays in wildlife and for the surveillance of zoonotic agents along the livestock-wildlife-human interface. |
format | Online Article Text |
id | pubmed-10368751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103687512023-07-27 Development of conjugated secondary antibodies for wildlife disease surveillance Ochai, Sunday O. Crafford, Jan E. Kamath, Pauline L. Turner, Wendy C. van Heerden, Henriette Front Immunol Immunology Disease monitoring in free-ranging wildlife is a challenge and often relies on passive surveillance. Alternatively, proactive surveillance that relies on the detection of specific antibodies could give more reliable and timely insight into disease presence and prevalence in a population, especially if the evidence of disease occurs below detection thresholds for passive surveillance. Primary binding assays, like the indirect ELISA for antibody detection in wildlife, are hampered by a lack of species-specific conjugates. In this study, we developed anti-kudu (Tragelaphus strepsiceros) and anti-impala (Aepyceros melampus) immunoglobulin-specific conjugates in chickens and compared them to the binding of commercially available protein-G and protein-AG conjugates, using an ELISA-based avidity index. The conjugates were evaluated for cross-reaction with sera from other wild herbivores to assess future use in ELISAs. The developed conjugates had a high avidity of >70% against kudu and impala sera. The commercial conjugates (protein-G and protein-AG) had significantly low relative avidity (<20%) against these species. Eighteen other wildlife species demonstrated cross-reactivity with a mean relative avidity of >50% with the impala and kudu conjugates and <40% with the commercial conjugates. These results demonstrate that species-specific conjugates are important tools for the development and validation of immunoassays in wildlife and for the surveillance of zoonotic agents along the livestock-wildlife-human interface. Frontiers Media S.A. 2023-07-11 /pmc/articles/PMC10368751/ /pubmed/37503338 http://dx.doi.org/10.3389/fimmu.2023.1221071 Text en Copyright © 2023 Ochai, Crafford, Kamath, Turner and van Heerden https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ochai, Sunday O. Crafford, Jan E. Kamath, Pauline L. Turner, Wendy C. van Heerden, Henriette Development of conjugated secondary antibodies for wildlife disease surveillance |
title | Development of conjugated secondary antibodies for wildlife disease surveillance |
title_full | Development of conjugated secondary antibodies for wildlife disease surveillance |
title_fullStr | Development of conjugated secondary antibodies for wildlife disease surveillance |
title_full_unstemmed | Development of conjugated secondary antibodies for wildlife disease surveillance |
title_short | Development of conjugated secondary antibodies for wildlife disease surveillance |
title_sort | development of conjugated secondary antibodies for wildlife disease surveillance |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368751/ https://www.ncbi.nlm.nih.gov/pubmed/37503338 http://dx.doi.org/10.3389/fimmu.2023.1221071 |
work_keys_str_mv | AT ochaisundayo developmentofconjugatedsecondaryantibodiesforwildlifediseasesurveillance AT craffordjane developmentofconjugatedsecondaryantibodiesforwildlifediseasesurveillance AT kamathpaulinel developmentofconjugatedsecondaryantibodiesforwildlifediseasesurveillance AT turnerwendyc developmentofconjugatedsecondaryantibodiesforwildlifediseasesurveillance AT vanheerdenhenriette developmentofconjugatedsecondaryantibodiesforwildlifediseasesurveillance |